Biotechnology

With a new $17.5M financing, Forlong Biotechnology accelerates its promising IL-15 and IL-18 cancer drugs, aiming to redefine post-PD-1 immunotherapy.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

The Karen Toffler Charitable Trust names Deborah Westphal its first CEO, signaling a strategic shift to accelerate neuroscience innovation for a new generation.

New research on the gut-brain axis and smarter antibiotic use is transforming veterinary medicine, moving from theory to practice for healthier pets.

A breakthrough shell-less egg system hatches live chicks, paving the way for the moa's return and offering new hope for today's endangered birds.

Lexitas acquires Erie Retina Research, CASExERIE, and Element Erie to create an integrated platform, aiming to dominate ophthalmic clinical trials.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Rancho BioSciences' new OmicsHQ platform offers analysis-ready datasets, aiming to eliminate data cleanup and accelerate AI-driven drug discovery.

Natural Alternatives International posts a 23% sales surge but a wider net loss, betting on new financing and product innovation to fix profitability woes.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

With backing from Bain Capital and Armistice, the life sciences firm's latest offering aims to fund its push to automate pharmaceutical quality control.

A PIF company becomes the first Saudi entity to join a top global genomics forum, a strategic move under Vision 2030 to shape the future of healthcare.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

As Avid Bioservices scales up, new Chief People Officer Maria Ebro Andreasen is tasked with building a talent pipeline in a fiercely competitive market.

With a new CSO known for pushing rare disease drugs to market, Arbor Biotechnologies signals a strategic shift from platform discovery to clinical execution.

Quince Therapeutics' drug LAM-001 posts strong Phase 2a data, showing meaningful functional gains for patients with severe pulmonary hypertension.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

A strategic investment from Olayan Financing Company positions MS Pharma to dominate the MENA biologics market, fueling Saudi Arabia's Vision 2030 goals.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.